focus -WSS

focus

author：fashion 2025-09-28 11:20:51 - browse：42

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA official pushes for dedicated emerging pathogens team

WSS

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Elizabeth Warren probes abortion access

White House launches permanent pandemic office

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

CDC backtracks, saying fully vaccinated people can go maskless indoors

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

hotspot

focus

focus

The cancer drug shortage isn’t new — and neither are the solutions

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Bright Health sells Medicare Advantage business to Molina

STAT reporters are Pulitzer Prize finalists for investigative reporting

Activists slam private health insurers over coverage restrictions

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Alkermes shareholders re

ALS treatment from Biogen, Ionis fails in study

Apple is now the first public company to be valued at $3 trillion

Russian special forces kill a gunman who broke into a private house near Moscow

hotspot

New rules on organ donation and transplantation 'will bring chaos'

Abbott's new stent may help patients with peripheral artery disease

Oak Street deal isn't the answer to health care's woes

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

STAT reporters are Pulitzer Prize finalists for investigative reporting

entertainment

knowledge

knowledge

hotspot